Parkinson's disease progression at 30 years: A study of subthalamic deep brain-stimulated patients

Brain

Volumn 134, Issue 7, 2011, Pages 2074-2084

  Merola, Aristide ^a   Zibetti, Maurizio ^a   Angrisano, Serena ^a   Rizzi, Laura ^a   Ricchi, Valeria ^a   Artusi, Carlo A ^a   Lanotte, Michele ^a   Rizzone, Mario G ^a   Lopiano, Leonardo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

DBS; levodopa; longitudinal; motor complications; Parkinson's disease; subthalamic nucleus

Indexed keywords

DOPAMINE; LEVODOPA;

ADULT; AGED; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; CONSTIPATION; DAILY LIFE ACTIVITY; DEMENTIA; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; DYSPHAGIA; FALLING; FEMALE; FOLLOW UP; HALLUCINATION; HUMAN; MALE; MOOD DISORDER; NEUROPSYCHOLOGICAL TEST; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATIENT ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; SPEECH DISORDER; SUBTHALAMIC NUCLEUS; TREATMENT RESPONSE; URINE INCONTINENCE;

ACTIVITIES OF DAILY LIVING; AGED; COGNITION DISORDERS; COHORT STUDIES; CONSTIPATION; DEEP BRAIN STIMULATION; DEGLUTITION DISORDERS; DEMENTIA; DEPRESSION; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; GAIT DISORDERS, NEUROLOGIC; HALLUCINATIONS; HUMANS; HYPOTENSION, ORTHOSTATIC; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; POSTURAL BALANCE; PSYCHIATRIC STATUS RATING SCALES; SPEECH DISORDERS; SUBTHALAMIC NUCLEUS; TIME FACTORS; URINARY INCONTINENCE;

EID: 79959728337     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awr121     Document Type: Article

References (40)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edn. Washington, DC: American Psychiatric Association; 2000.
2. Aybek S, Gronchi-Perrin A, Berney A, Chiuve SC, Villemure JG, Burkhard PR, et al. Long-term cognitive profile and incidence of dementia after STN-DBS in Parkinson's disease. Mov Disord 2007; 22: 974-81. (Pubitemid 46999294)
3. Caballol N, Marti MJ, Tolosa E. Cognitive dysfunction and dementia in Parkinson disease. Mov Disord 2007; 22: S358-66. (Pubitemid 350134189)
4. Defer GL, Widner H, Marie RM, Remy P, Levivier M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-Parkinson's disease). Mov Disord 1999; 14: 572-84. (Pubitemid 30011449)
5. Derost PP, Ouchchane L, Morand D, Ulla M, Llorca PM, Barget M, et al. Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population? Neurology 2007; 68: 1345-55. (Pubitemid 46659085)
6. Diem-Zangerl A, Seppi K, Wenning GK, Trinka E, Ransmayr G, Oberaigner W, et al. Mortality in Parkinson's disease: a 20-year follow-up study. Mov Disord 2009; 24: 819-25.
7. Fahn S, Elton R. Members of the UParkinson's diseaseRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson's disease. Vol. Vol. 2. Florham Park, NJ: Macmillan Health Care Information; 1987. p. 153-63.
8. Fasano A, Romito LM, Daniele A, Piano C, Zinno M, Bentivoglio AR, et al. Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. Brain 2010; 133: 2664-76.
9. Hardy J, Lewis P, Revesz T, Lees A, Paisan-Ruiz C. The genetics of Parkinson's syndromes: a critical review. Curr Opin Genet Dev 2009; 19: 254-65.
10. Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007; 22: 2409-17. (Pubitemid 351155989)
11. Hely MA, Morris JG, Traficante R, Reid WG, O'Sullivan DJ, Williamson PM. The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999; 67: 300-7. (Pubitemid 29392588)
12. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005; 20: 190-9. (Pubitemid 40361122)
13. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-44.
14. Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord 2004; 19: 1043-9. (Pubitemid 39302836)
15. Inzelberg R, Polyniki A. Are genetic and sporadic Parkinson's disease patients equally susceptible to develop dementia? J Neurol Sci 2010; 289: 23-6.
16. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990; 40: 1529-34. (Pubitemid 20351344)
17. Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ. Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. Brain 2007; 130: 2123-8. (Pubitemid 47236624)
18. Kempster PA, O'Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 2010; 133: 1755-62.
19. Klein C, Djarmati A, Hedrich K, Schafer N, Scaglione C, Marchese R, et al. PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism. Eur J Hum Genet 2005; 13: 1086-93. (Pubitemid 43073617)
20. Klein C, Lohmann-Hedrich K. Impact of recent genetic findings in Parkinson's disease. Curr Opin Neurol 2007; 20: 453-64. (Pubitemid 47051994)
21. Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003; 349: 1925-34. (Pubitemid 37409709)
22. Lanotte MM, Rizzone M, Bergamasco B, Faccani G, Melcarne A, Lopiano L. Deep brain stimulation of the subthalamic nucleus: anatomical, neurophysiological, and outcome correlations with the effects of stimulation. J Neurol Neurosurg Psychiatry 2002; 72: 53-8. (Pubitemid 34073097)
23. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009; 373: 2055-66.
24. Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000; 342: 1560-7. (Pubitemid 30340501)
25. Marras C, Rochon P, Lang AE. Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol 2002; 59: 1724-8. (Pubitemid 35340482)
26. Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Rudolph A, et al. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology 2005; 64: 87-93. (Pubitemid 40082942)
27. Moro E, Lozano AM, Pollak P, Agid Y, Rehncrona S, Volkmann J, et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord 2010; 25: 578-86.
28. Ory-Magne F, Brefel-Courbon C, Simonetta-Moreau M, Fabre N, Lotterie JA, Chaynes P, et al. Does ageing influence deep brain stimulation outcomes in Parkinson's disease? Mov Disord 2007; 22: 1457-63. (Pubitemid 47280632)
29. Parent B, Awan N, Berman SB, Suski V, Moore R, Crammond D, et al. The relevance of age and disease duration for intervention with sub-thalamic nucleus deep brain stimulation surgery in Parkinson disease. J Neurosurg 2011; 114: 927-31.
30. Post B, Merkus MP, de Haan RJ, Speelman JD. Prognostic factors for the progression of Parkinson's disease: a systematic review. Mov Disord 2007; 22: 1839-51. (Pubitemid 350134194)
31. Rajput AH, Sitte HH, Rajput A, Fenton ME, Pifl C, Hornykiewicz O. Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation. Neurology 2008; 70: 1403-10. (Pubitemid 351521932)
32. Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A. Course in Parkinson disease subtypes: a 39-year clinicopathologic study. Neurology 2009; 73: 206-12.
33. Rodriguez-Oroz MC, Obeso JA, Lang AE, Houeto JL, Pollak P, Rehncrona S, et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 2005; 128: 2240-9. (Pubitemid 41407964)
34. Russmann H, Ghika J, Villemure JG, Robert B, Bogousslavsky J, Burkhard PR, et al. Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years. Neurology 2004; 63: 1952-4. (Pubitemid 39532401)
35. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009; 132: 2947-57.
36. Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson's disease revisited-clinical features, natural history, and mortality. Mov Disord 1998; 13: 885-94. (Pubitemid 28517664)
37. St George RJ, Nutt JG, Burchiel KJ, Horak FB. A meta-regression of the long-term effects of deep brain stimulation on balance and gait in Parkinson's disease. Neurology 2010; 75: 1292-9.
38. Tsai ST, Lin SH, Chou YC, Pan YH, Hung HY, Li CW, et al. Prognostic factors of subthalamic stimulation in Parkinson's disease: a comparative study between short- and long-term effects. Stereotact Funct Neurosurg 2009; 87: 241-8.
39. Welter ML, Houeto JL, Tezenas du Montcel S, Mesnage V, Bonnet AM, Pillon B, et al. Clinical predictive factors of subthalamic stimulation in Parkinson's disease. Brain 2002; 125: 575-83. (Pubitemid 34194412)
40. Zetusky WJ, Jankovic J, Pirozzolo FJ. The heterogeneity of Parkinson's disease: clinical and prognostic implications. Neurology 1985; 35: 522-6. (Pubitemid 15085070)